{
    "table_name": "HTAN_VERSIONED.CLINICAL_TIER1_THERAPY_R5",
    "table_fullname": "HTAN_1.HTAN_VERSIONED.CLINICAL_TIER1_THERAPY_R5",
    "column_names": [
        "TREATMENT_ARM",
        "TREATMENT_EFFECT",
        "INITIAL_DISEASE_STATUS",
        "ENTITYID",
        "ID",
        "TREATMENT_DOSE",
        "DAYS_TO_TREATMENT_END",
        "HTAN_CENTER",
        "TREATMENT_EFFECT_INDICATOR",
        "TREATMENT_TYPE",
        "COMPONENT",
        "MANIFEST_VERSION",
        "REASON_TREATMENT_ENDED",
        "THERAPEUTIC_AGENTS",
        "CHEMO_CONCURRENT_TO_RADIATION",
        "REGIMEN_OR_LINE_OF_THERAPY",
        "TREATMENT_FREQUENCY",
        "TREATMENT_OR_THERAPY",
        "MANIFEST_ID",
        "TREATMENT_ANATOMIC_SITE",
        "TREATMENT_INTENT_TYPE",
        "TREATMENT_DOSE_UNITS",
        "NUMBER_OF_CYCLES",
        "DAYS_TO_TREATMENT_START",
        "TREATMENT_OUTCOME",
        "HTAN_PARTICIPANT_ID"
    ],
    "column_types": [
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "NUMBER",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT",
        "TEXT"
    ],
    "description": [
        "Text term used to describe the treatment arm assigned to a patient at the time eligibility is determined.",
        "The text term used to describe the pathologic effect a treatment(s) had on the tumor.",
        "The text term used to describe the status of the patient's malignancy when the treatment began.",
        "Synapse ID of entity",
        "Unique identifier of entity e.g. a96059eb-81af-4b24-ae50-9242c0d8f819",
        "The numeric value used to describe the dose of an agent the patient received.",
        "Number of days between the date used for index and the date the treatment ended. If not applicable please enter 'Not Applicable'",
        "Name of HTAN Center e.g. HTAN HTAPP",
        "The text term used to indicate whether the treatment had an effect on the patient.",
        "Text term that describes the kind of treatment administered.",
        "Category of metadata (e.g. Diagnosis, Biospecimen, scRNA-seq Level 1, etc.); provide the same one for all items/rows.",
        "Latest version of metadata manifest",
        "The text term used to describe the reason a specific treatment or regimen ended.",
        "Text identification of the individual agent(s) used as part of a treatment regimen.",
        "The text term used to describe whether the patient was receiving chemotherapy concurrent to radiation.",
        "The text term used to describe the regimen or line of therapy.",
        "The text term used to describe the frequency the patient received an agent or regimen.",
        "A yes/no/unknown/not applicable indicator related to the administration of therapeutic agents received.",
        "Synapse ID of manifest containing file annotation",
        "The text term used to describe the anatomic site of resection; biopsy; tissue or organ of biospecimen origin; progression or recurrent disease; treatment",
        "Text term to identify the reason for the administration of a treatment regimen. [Manually-curated]",
        "The text term used to describe the dose units of an agent the patient received.",
        "The numeric value used to describe the number of cycles of a specific treatment or regimen the patient received.",
        "Number of days between the date used for index and the date the treatment started. If not applicable please enter 'Not Applicable'",
        "Text term that describes the patient's final outcome after the treatment was administered.",
        "HTAN ID associated with a patient based on HTAN ID SOP (eg HTANx_yyy )"
    ],
    "sample_rows": [
        {
            "DAYS_TO_TREATMENT_START": "21417.0",
            "CHEMO_CONCURRENT_TO_RADIATION": "no",
            "NUMBER_OF_CYCLES": null,
            "TREATMENT_INTENT_TYPE": "Cancer Control",
            "COMPONENT": "Therapy",
            "DAYS_TO_TREATMENT_END": "21487.0",
            "INITIAL_DISEASE_STATUS": "Residual Disease",
            "TREATMENT_FREQUENCY": null,
            "REASON_TREATMENT_ENDED": null,
            "TREATMENT_TYPE": "Chemotherapy",
            "THERAPEUTIC_AGENTS": null,
            "TREATMENT_DOSE_UNITS": null,
            "TREATMENT_ARM": null,
            "TREATMENT_OUTCOME": "Complete Response",
            "REGIMEN_OR_LINE_OF_THERAPY": "1.0",
            "TREATMENT_ANATOMIC_SITE": "Lung NOS",
            "ENTITYID": null,
            "TREATMENT_OR_THERAPY": "yes",
            "HTAN_PARTICIPANT_ID": "HTA3_80052",
            "TREATMENT_EFFECT": "Complete Necrosis (No Viable Tumor)",
            "TREATMENT_EFFECT_INDICATOR": "yes",
            "TREATMENT_DOSE": null,
            "ID": "a70cdf2a-4094-4273-b377-be181a13ef10",
            "HTAN_CENTER": "HTAN BU",
            "MANIFEST_ID": "syn39148156",
            "MANIFEST_VERSION": 4
        },
        {
            "DAYS_TO_TREATMENT_START": "28916",
            "CHEMO_CONCURRENT_TO_RADIATION": "No",
            "NUMBER_OF_CYCLES": null,
            "TREATMENT_INTENT_TYPE": "Adjuvant",
            "COMPONENT": "Therapy",
            "DAYS_TO_TREATMENT_END": null,
            "INITIAL_DISEASE_STATUS": "Initial Diagnosis",
            "TREATMENT_FREQUENCY": null,
            "REASON_TREATMENT_ENDED": null,
            "TREATMENT_TYPE": "Immunotherapy (Including Vaccines)",
            "THERAPEUTIC_AGENTS": "Pembrolizumab",
            "TREATMENT_DOSE_UNITS": null,
            "TREATMENT_ARM": null,
            "TREATMENT_OUTCOME": "Treatment Ongoing",
            "REGIMEN_OR_LINE_OF_THERAPY": "1st",
            "TREATMENT_ANATOMIC_SITE": "Lymph nodes of axilla or arm",
            "ENTITYID": null,
            "TREATMENT_OR_THERAPY": "Yes",
            "HTAN_PARTICIPANT_ID": "HTA5_1430",
            "TREATMENT_EFFECT": "No Necrosis",
            "TREATMENT_EFFECT_INDICATOR": "Yes",
            "TREATMENT_DOSE": "200",
            "ID": "216599db-e4bc-443c-bba8-a148309f27da",
            "HTAN_CENTER": "HTAN DFCI",
            "MANIFEST_ID": "syn51360962",
            "MANIFEST_VERSION": 8
        },
        {
            "DAYS_TO_TREATMENT_START": "23445",
            "CHEMO_CONCURRENT_TO_RADIATION": "No",
            "NUMBER_OF_CYCLES": "12 or 13",
            "TREATMENT_INTENT_TYPE": "Adjuvant",
            "COMPONENT": "Therapy",
            "DAYS_TO_TREATMENT_END": "23781.0",
            "INITIAL_DISEASE_STATUS": "Recurrent Disease",
            "TREATMENT_FREQUENCY": null,
            "REASON_TREATMENT_ENDED": "Course of Therapy Completed",
            "TREATMENT_TYPE": "Immunotherapy (Including Vaccines)",
            "THERAPEUTIC_AGENTS": "Pembrolizumab",
            "TREATMENT_DOSE_UNITS": null,
            "TREATMENT_ARM": null,
            "TREATMENT_OUTCOME": "No Measurable Disease",
            "REGIMEN_OR_LINE_OF_THERAPY": "1st",
            "TREATMENT_ANATOMIC_SITE": "Lymph nodes of inguinal region or leg",
            "ENTITYID": null,
            "TREATMENT_OR_THERAPY": "Yes",
            "HTAN_PARTICIPANT_ID": "HTA5_1587",
            "TREATMENT_EFFECT": "No Necrosis",
            "TREATMENT_EFFECT_INDICATOR": "Yes",
            "TREATMENT_DOSE": null,
            "ID": "5472d08a-b084-418c-a79c-7ac5da851418",
            "HTAN_CENTER": "HTAN DFCI",
            "MANIFEST_ID": "syn51360962",
            "MANIFEST_VERSION": 8
        },
        {
            "DAYS_TO_TREATMENT_START": "27153",
            "CHEMO_CONCURRENT_TO_RADIATION": "No",
            "NUMBER_OF_CYCLES": "1",
            "TREATMENT_INTENT_TYPE": "Adjuvant",
            "COMPONENT": "Therapy",
            "DAYS_TO_TREATMENT_END": "27153.0",
            "INITIAL_DISEASE_STATUS": "Initial Diagnosis",
            "TREATMENT_FREQUENCY": null,
            "REASON_TREATMENT_ENDED": "Adverse Therapy Event",
            "TREATMENT_TYPE": "Immunotherapy (Including Vaccines)",
            "THERAPEUTIC_AGENTS": "Pembrolizumab",
            "TREATMENT_DOSE_UNITS": null,
            "TREATMENT_ARM": null,
            "TREATMENT_OUTCOME": "No Measurable Disease",
            "REGIMEN_OR_LINE_OF_THERAPY": "1st",
            "TREATMENT_ANATOMIC_SITE": "Lymph nodes of inguinal region or leg",
            "ENTITYID": null,
            "TREATMENT_OR_THERAPY": "Yes",
            "HTAN_PARTICIPANT_ID": "HTA5_1791",
            "TREATMENT_EFFECT": "No Necrosis",
            "TREATMENT_EFFECT_INDICATOR": "Yes",
            "TREATMENT_DOSE": "200",
            "ID": "13bbb55a-7319-4f3c-8be7-c638e6aaa049",
            "HTAN_CENTER": "HTAN DFCI",
            "MANIFEST_ID": "syn51360962",
            "MANIFEST_VERSION": 8
        },
        {
            "DAYS_TO_TREATMENT_START": "21430",
            "CHEMO_CONCURRENT_TO_RADIATION": "No",
            "NUMBER_OF_CYCLES": null,
            "TREATMENT_INTENT_TYPE": "Adjuvant",
            "COMPONENT": "Therapy",
            "DAYS_TO_TREATMENT_END": null,
            "INITIAL_DISEASE_STATUS": "Initial Diagnosis",
            "TREATMENT_FREQUENCY": null,
            "REASON_TREATMENT_ENDED": null,
            "TREATMENT_TYPE": "Immunotherapy (Including Vaccines)",
            "THERAPEUTIC_AGENTS": "Nivolumab",
            "TREATMENT_DOSE_UNITS": null,
            "TREATMENT_ARM": null,
            "TREATMENT_OUTCOME": "Treatment Ongoing",
            "REGIMEN_OR_LINE_OF_THERAPY": "1st",
            "TREATMENT_ANATOMIC_SITE": "Lung NOS",
            "ENTITYID": null,
            "TREATMENT_OR_THERAPY": "Yes",
            "HTAN_PARTICIPANT_ID": "HTA5_1847",
            "TREATMENT_EFFECT": "No Necrosis",
            "TREATMENT_EFFECT_INDICATOR": "Yes",
            "TREATMENT_DOSE": "480",
            "ID": "d6742ec6-0629-4afa-bc2a-a18037b79a86",
            "HTAN_CENTER": "HTAN DFCI",
            "MANIFEST_ID": "syn51360962",
            "MANIFEST_VERSION": 8
        }
    ]
}